CClinicalTrials.gg
CompletedNCT00312078Updated Nov 1, 2007

Effect of Yogurt on Minimal Hepatic Encephalopathy

An interventional study of Yogurt Supplementation in Cirrhosis and Minimal Hepatic Encephalopathy, sponsored by Medical College of Wisconsin. Completed at 1 site in United States. Open to participants aged 24 Years to 65 Years. Per ClinicalTrials.gov, last updated 2007-11-01.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
24 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether a special yogurt can improve performance on certain tests of intelligence and decrease liver inflammation in patients with cirrhosis.

Read the detailed description

Introduction: Cirrhosis is one of the leading causes of death in the United States. Minimal hepatic encephalopathy (MHE) is a significant complication of cirrhosis, which is often not treated because of perceived subclinical nature of this condition and the adverse effects and expense of available medications such as lactulose or rifaximin. There is evidence that small intestinal bacterial overgrowth can contribute to the development of MHE and cirrhosis in murine and human studies. Probiotics are live bacteria that can modify the indigenous intestinal bacterial flora and have been recently used in the treatment of hepatic encephalopathy in patients with cirrhosis.

Our aim is to evaluate the effect of probiotic supplementation via yogurt on liver function and inflammatory markers of bacterial translocation and psychometric test performance in cirrhotic patients with MHE in a prospective pilot trial.

Methods: 30 patients with MHE 2:1 i.e. 20 will be randomized into supplementation with yogurt to be taken 6 ounces twice a day for 60 days and 10 patients will be followed up without yogurt supplementation. All patients will undergo liver function tests, basic metabolic panel, INR, venous ammonia, IL-6 and TNF-alpha at baseline, 30 days and at 60 days. All patients will also undergo psychometric testing with number connection test A, digit symbol test, block design and inhibitory control test at baseline and 60 days. Regular questioning about adherence to yogurt. Collection of yogurt tops as proof of yogurt consumption and review of intake diary will be done at 30 and 60 days from patients randomized to yogurt supplementation.

Importance: There has been only one human study on the modification of gut flora as a therapeutic tool for improvement of MHE in cirrhosis, however that study included alcoholic liver disease and comprised of Chinese patients, therefore etiologies of liver diseases studied were different from those predominant in the United States. Since MHE can adversely affect quality of life and overall prognosis, simple, targeted therapies are needed to treat it. We believe that our pilot study will help delineate human gut flora as a definite target for therapy of cirrhosis and MHE and pave the way for future large-scale studies on this subject.

02

Conditions studied

  • Cirrhosis
  • Minimal Hepatic Encephalopathy

Keywords

  • Minimal Hepatic Encephalopathy
  • Cirrhosis
03

In context

Hepatic Encephalopathy

218 studies on the registry are indexed under Hepatic Encephalopathy; 48 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 148 interventional studies indexed under Hepatic Encephalopathy.

Browse Hepatic Encephalopathy studies →

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 540 studies on the registry; 119 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 56 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Cirrhosis diagnosed on clinical grounds (within 3 months of enrollment)
  • MHE diagnosed by abnormalities in a psychometric battery (NCT-A,BDT,DST and ICT)

Exclusion criteria

Exclusion criteria:

  • Current or recent (\< 6 month) use of alcohol
  • Co-existing cause of liver dysfunction
  • Use of antibiotics within last 6 weeks
  • Infection or gastrointestinal hemorrhage within the last 6 weeks
  • Hepatocellular carcinoma
  • Psychoactive drug use, including interferon concurrently
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Interventions

  • Dietary supplementYogurt Supplementation
06

What researchers measure

Primary outcomes

  1. Reversal of minimal hepatic encephalopathy

Secondary outcomes

  1. Decrease in AST/ALT

07

Study locations

1 site
  • GCRC Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00312078
Lead sponsor
Medical College of Wisconsin
Collaborators
National Center for Research Resources (NCRR)
First posted
Apr 7, 2006
Start date
Nov 2005
Completion
Apr 2007
Last update
Nov 1, 2007

Study contacts

Jasmohan S Bajaj, MD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion